MLchartDataset catalogue

anti-latent TGFb1 monoclonal antibody RO7496353

Term · Oncology and biomedicine · MLC-T-ONC-010857

A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, anti-latent TGFb1 monoclonal antibody RO7496353 targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.

Table 1. Record
IdentifierMLC-T-ONC-010857
FieldOncology and biomedicine
Synonymsanti-latent TGF-beta1 monoclonal antibody RO7496353; anti-latent TGF-beta 1 monoclonal antibody RO7496353; anti-latent TGF-beta1 monoclonal antibody SOF10; anti-latent TGF-beta1 monoclonal antibody RG6440
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010857",
  "term": "anti-latent TGFb1 monoclonal antibody RO7496353",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, anti-latent TGFb1 monoclonal antibody RO7496353 targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.",
  "synonyms": [
    "anti-latent TGF-beta1 monoclonal antibody RO7496353",
    "anti-latent TGF-beta 1 monoclonal antibody RO7496353",
    "anti-latent TGF-beta1 monoclonal antibody SOF10",
    "anti-latent TGF-beta1 monoclonal antibody RG6440"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-latent-tgfb1-monoclonal-antibody-ro7496353/"
}

Record 1,974 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.